Table 1.
Patient Characteristics
| Characteristics | Discovery Cohort | Validation Cohort | |
|---|---|---|---|
| HIV-1 Infected (n = 15) | Non-HIV-1 Infected (n = 30) | Non-HIV-1 Infected (n=41) | |
| Gender – no. (%) | | ||
| Male | 12 (80.0) | 17 (56.7) | 26 (63) |
| Female | 3 (20.0) | 13 (43.3) | 15 (37) |
| Age - yr | |||
| Median | 54 | 62 | 63 |
| Range | 30–73 | 47–82 | 38–80 |
| Smoking status – no. (%) | |||
| Never | 2 (13.3) | 1 (3.3) | 6 (15) |
| Former/current | 12 (80.0) | 26 (86.7) | 35 (85) |
| Unknown | 1 (6.7) | 3 (10.0) | 0 |
| Tumor type – no. (%) | |||
| Lung* | 12 (80.0) | 29 (96.7) | 41 (100) |
| Melanoma | 2 (13.3) | 0 (0.0) | 0 |
| Bladder | 1 (6.7) | 0 (0.0) | 0 |
| Mesothelioma | 0 (0.0) | 1 (3.3) | 0 |
| Stage – no. (%) | |||
| Stage III | 1 (6.7) | 2 (6.7) | 5 (12) |
| Stage IV | 14 (93.3) | 28 (93.3) | 36 (88) |
| ICI Treatment – no. (%) | |||
| Durvalumab | 15 (100) | 2 (6.7) | 4 (10) |
| Nivolumab | 0 (0.0) | 18 (60.0) | 19 (46) |
| Pembrolizumab | 0 (0.0) | 5 (16.7) | 11 (27) |
| Atezolizumab | 0 (0.0) | 3 (10.0) | 4 (10) |
| Others | 0 (0.0) | 2 (6.7) | 3 (7) |
| Treatment Regimen – no. (%) | |||
| Single | 15 (100) | 19 (63.3) | 19 (46) |
| With chemotherapy | 0 (0.0) | 5 (16.6) | 13 (32) |
| Other combination | 0 (0.0) | 6 (20.1) | 9 (22) |
| No. of prior systemic therapies – no. (%) | |||
| 0 | 8 (53.3) | 12 (40.0) | 24 (58) |
| 1 | 4 (26.7) | 14 (46.7) | 7 (17) |
| ≥ 2 | 3 (20.0) | 4 (13.3) | 10 (24) |
| cART – no. (%) | |||
| NRTIs + INSTIs | 12 (80.0) | 0 (0.0) | 0 |
| NRTIs + non-INSTIs | 3 (20.0) | 0 (0.0) | 0 |
Notes: *Lung cancer histology in the discovery cohort: adenocarcinoma 31 (69%), squamous carcinoma 8 (18%), small cell lung cancer 8 (18%); lung cancer histology in the validation cohort: adenocarcinoma 26 (63%), squamous 14 (34%), adeno-squamous 1 (2%).
Abbreviations: c ART, combination antiretroviral therapy; NRTIs, nucleoside reverse transcriptase inhibitors; ICI. Immune check point inhibitor; INSTIs, integrase strand transfer inhibitors; yr, year.